
Breakthrough in Melanoma Treatment: OPM-101 Offers Hope for Resistant Cases
Rising melanoma cases and therapy resistance highlight the need for novel treatments like OPM-101, a RIPK2 inhibitor by Oncodesign Precision Medicine (OPM). OPM-101 shows promising synergy with pembrolizumab, enhancing tumor eradication and immune response in resistant melanoma. The REVERT trial will introduce